Clarifying lysosomal storage diseases

Trends in Neurosciences

Volumn 34, Issue 8, 2011, Pages 401-410

  Schultz, Mark L ^a,b   Tecedor, Luis ^a   Chang, Michael ^a   Davidson, Beverly L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; CYCLODEXTRIN; GENTAMICIN; MIGLUSTAT;

AUTOPHAGY; BIOCHEMISTRY; CELL THERAPY; CELL VIABILITY; CLINICAL TRIAL; EXOCYTOSIS; GAUCHER DISEASE; GENE THERAPY; HUMAN; LYSOSOME STORAGE DISEASE; MOLECULAR MECHANICS; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; EXOCYTOSIS; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; PROTEIN TRANSPORT; PROTEINS;

EID: 79960961365     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2011.05.006     Document Type: Review

References (108)

1. Vitner E.B., et al. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 2010, 285:20423-20427.
2. Bellettato C.M., Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 2010, 33:347-362.
3. Ballabio A., Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 2009, 1793:684-696.
4. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 2009, 15:89-100.
5. Eng C.M., et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68:711-722.
6. Liu G., et al. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 2005, 25:9321-9327.
7. Sardiello M., et al. A gene network regulating lysosomal biogenesis and function. Science 2009, 325:473-477.
8. Saftig P., et al. Lysosomal membrane proteins: life between acid and neutral conditions. Biochem. Soc. Trans. 2010, 38:1420-1423.
9. Saftig P., Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell. Biol. 2009, 10:623-635.
10. Reczek D., et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007, 131:770-783.
11. Blanz J., et al. Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. Hum. Mol. Genet. 2010, 19:563-572.
12. Lee J.H., et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010, 141:1146-1158.
13. Cox T.M. Biomarkers in lysosomal storage diseases. Fabry Disease: Perspectives from 5 Years of FOS 2006, Oxford Pharma Genesis. A. Mehta (Ed.).
14. Wisniewski K.E., et al. Increased urine concentration of subunit c of mitochondrial ATP synthase in neuronal ceroid lipofuscinoses patients. J. Inherit. Metab. Dis. 1994, 17:205-210.
15. Goebel H.H. The neuronal ceroid-lipofuscinoses. Semin. Pediatr. Neurol. 1996, 3:270-278.
16. Vitry S., et al. Storage vesicles in neurons are related to Golgi complex alterations in mucopolysaccharidosis IIIB. Am. J. Pathol. 2010, 177:2984-2999.
17. Raychowdhury M.K., et al. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum. Mol. Genet. 2004, 13:617-627.
18. Pearce D.A., et al. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease. Nat. Genet. 1999, 22:55-58.
19. Brett C.L., et al. Genome-wide analysis reveals the vacuolar pH-stat of Saccharomyces cerevisiae. PLoS ONE 2011, 6:e17619.
20. Zhang W., et al. V-ATPase V0 sector subunit a1 in neurons is a target of calmodulin. J. Biol. Chem. 2008, 283:294-300.
21. Williamson W.R., et al. A dual function of V0-ATPase a1 provides an endolysosomal degradation mechanism in Drosophila melanogaster photoreceptors. J. Cell Biol. 2010, 189:885-899.
22. Marshansky V., Futai M. The V-type H1-ATPase in vesicular trafficking: targeting, regulation and function. Curr. Opin. Cell Biol. 2008, 20:415-426.
23. Weimer R.M., Jorgensen E.M. Controversies in synaptic vesicle exocytosis. J. Cell Sci. 2003, 116:3661-3666.
24. Mijaljica D., et al. V-ATPase engagement in autophagic processes. Autophagy 2011, 7:666-668.
25. Sobota J.A., et al. Inhibitors of the V0 subunit of the vacuolar H1-ATPase prevent segregation of lysosomal- and secretory-pathway proteins. J. Cell Sci. 2009, 122:3542-3553.
26. Zhang Z., et al. Vesicular ATPase inserted into the plasma membrane of motor terminals by exocytosis alkalinizes cytosolic pH and facilitates endocytosis. Neuron 2010, 68:1097-1108.
27. Hiesinger P.R., et al. The v-ATPase V0 subunit a1 is required for a late step in synaptic vesicle exocytosis in Drosophila. Cell 2005, 121:607-620.
28. Schmidt C., et al. Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. Mol. Psychiatry 2008, 13:953-969.
29. Xing S.L., et al. Neuronal cell surface ATP synthase mediates synthesis of extracellular ATP and regulation of intracellular pH. Cell Biol. Int. 2011, 35:81-86.
30. Padilla-Lopez S., Pearce D.A. Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity to regulate pH imbalance in the vacuole. J. Biol. Chem. 2006, 281:10273-10280.
31. Korolchuk V.I., et al. Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol. 2011, 13:453-460.
32. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
33. Yue Z., et al. The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases. Biochim. Biophys. Acta 2009, 1793:1496-1507.
34. Bejarano E., Cuervo A.M. Chaperone-mediated autophagy. Proc. Am. Thorac. Soc. 2010, 7:29-39.
35. Hara T., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
36. Komatsu M., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
37. Cao Y., et al. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 2006, 281:20483-20493.
38. Fukuda T., et al. Autophagy and lysosomes in Pompe disease. Autophagy 2006, 2:318-320.
39. Jennings J.J., et al. Mitochondrial aberrations in mucolipidosis Type IV. J. Biol. Chem. 2006, 281:39041-39050.
40. Pacheco C.D., et al. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum. Mol. Genet. 2007, 16:1495-1503.
41. Settembre C., et al. A block of autophagy in lysosomal storage disorders. Hum. Mol. Genet. 2008, 17:119-129.
42. Venkatachalam K., et al. Motor deficit in a Drosophila model of mucolipidosis type IV due to defective clearance of apoptotic cells. Cell 2008, 135:838-851.
43. Curcio-Morelli C., et al. Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiol. Dis. 2010, 40:370-377.
44. Fukuda T., et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. 2006, 14:831-839.
45. Raben N., et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder: murine Pompe disease. Autophagy 2010, 6:1078-1089.
46. Chang J.W., et al. Lithium rescues the impaired autophagy process in CbCln3(Deltaex7/8/Deltaex7/8) cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition. J. Neurochem. 2011, 116:659-668.
47. Watase K., et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007, 4:e182.
48. Pasquali L., et al. Intracellular pathways underlying the effects of lithium. Behav. Pharmacol. 2010, 21:473-492.
49. LaPlante J.M., et al. Lysosomal exocytosis is impaired in mucolipidosis type IV. Mol. Genet. Metab. 2006, 89:339-348.
50. Xu S., et al. Defects of synaptic vesicle turnover at excitatory and inhibitory synapses in Niemann-Pick C1-deficient neurons. Neuroscience 2010, 167:608-620.
51. Yogalingam G., et al. Neuraminidase 1 is a negative regulator of lysosomal exocytosis. Dev. Cell 2008, 15:74-86.
52. Newell-Litwa K., et al. Roles of BLOC-1 and adaptor protein-3 complexes in cargo sorting to synaptic vesicles. Mol. Biol. Cell 2009, 20:1441-1453.
53. Nizami S., et al. Presynaptic roles of intracellular Ca(21) stores in signalling and exocytosis. Biochem. Soc. Trans. 2010, 38:529-535.
54. Lang T., Jahn R. Core proteins of the secretory machinery. Handb. Exp. Pharmacol. 2008, 107-127.
55. Rao S.K., et al. Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis. J. Biol. Chem. 2004, 279:20471-20479.
56. Fraldi A., et al. Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J. 2010, 29:3607-3620.
57. Choudhury A., et al. Elevated endosomal cholesterol levels in Niemann-Pick cells inhibit rab4 and perturb membrane recycling. Mol. Biol. Cell 2004, 15:4500-4511.
58. Dong X.P., et al. TRP channels of intracellular membranes. J. Neurochem. 2010, 113:313-328.
59. LaPlante J.M., et al. Identification and characterization of the single channel function of human mucolipin-1 implicated in mucolipidosis type IV, a disorder affecting the lysosomal pathway. FEBS Lett. 2002, 532:183-187.
60. Dong X.P., et al. Activating mutations of the TRPML1 channel revealed by proline-scanning mutagenesis. J. Biol. Chem. 2009, 284:32040-32052.
61. Zlokovic B.V. Neurodegeneration and the neurovascular unit. Nat. Med. 2010, 16:1370-1371.
62. Chen Y.H., et al. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 2009, 15:1215-1218.
63. Sands M.S., Davidson B.L. Gene therapy for lysosomal storage diseases. Mol. Ther. 2006, 13:839-849.
64. Sands M.S., Haskins M.E. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr. 2008, 97(Suppl.):22-27.
65. Malnar M., et al. Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the beta-secretase pathway. Biochim. Biophys. Acta 2010, 1802:682-691.
66. Tamboli I.Y., et al. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J. Neurosci. 2011, 31:1837-1849.
67. Zhou X., et al. Deletion of PIK3C3/Vps34 in sensory neurons causes rapid neurodegeneration by disrupting the endosomal but not the autophagic pathway. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9424-9429.
68. Doyle J.P., et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 2008, 135:749-762.
69. Rohrbach M., Clarke J.T. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007, 67:2697-2716.
70. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 2009, 1:268-279.
71. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 2011, 12:341-355.
72. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genet. 2011, 12:301-315.
73. McCaughan K.K., et al. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:5431-5435.
74. Keeling K.M., et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum. Mol. Genet. 2001, 10:291-299.
75. Sleat D.E., et al. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 2001, 5(Suppl. A):57-62.
76. Nudelman I., et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg. Med. Chem. 2010, 18:3735-3746.
77. Langmade S.J., et al. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13807-13812.
78. Davidson C.D., et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 2009, 4:e6951.
79. Liu B., et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2377-2382.
80. Glass C.K., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
81. Settembre C., et al. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4506-4511.
82. Oswald M.J., et al. Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol. Dis. 2005, 20:49-63.
83. Wu Y.P., Proia R.L. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8425-8430.
84. Sawkar A.R., et al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 2005, 12:1235-1244.
85. Fan J.Q., et al. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 1999, 5:112-115.
86. Suzuki Y. Chemical chaperone therapy for GM1-gangliosidosis. Cell. Mol. Life Sci. 2008, 65:351-353.
87. Lieberman R.L, et al. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 2009, 48:4816-4827.
88. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
89. Braulke T., Bonifacino J.S. Sorting of lysosomal proteins. Biochim. Biophys. Acta 2009, 1793:605-614.
90. Luzio J.P., et al. Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 2007, 8:622-632.
91. Choi J.O., et al. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer. J. Biomed. Sci. 2010, 17:26.
92. Marshall J., et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE 2010, 5:e15033.
93. Enquist I.B., et al. Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells 2009, 27:744-752.
94. Baek R.C., et al. AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS ONE 2010, 5:e13468.
95. Elliot-Smith E., et al. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol. Genet. Metab. 2008, 94:204-211.
96. Cachon-Gonzalez M.B., et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10373-10378.
97. Maegawa G.H., et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 2007, 282:9150-9161.
98. Wang D., et al. Short-term, high dose enzyme replacement therapy in sialidosis mice. Mol. Genet. Metab. 2005, 85:181-189.
99. Ellinwood N.M., et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther. 2011, 19:251-259.
100. Fraldi A., et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum. Mol. Genet. 2007, 16:2693-2702.
101. Hemsley K.M., et al. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs: a proof of principle study. Mol. Genet. Metab. 2009, 98:383-392.
102. Heldermon C.D., et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol. Ther. 2010, 18:873-880.
103. Ficko-Blean E., et al. Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6560-6565.
104. Bielicki J., et al. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII. Mol. Genet. Metab. 2010, 101:370-382.
105. Hackett N.R., et al. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Hum. Gene Ther. 2005, 16:1484-1503.
106. Chang M., et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 2008, 16:649-656.
107. Seehafer S.S., et al. Immunosuppression alters disease severity in juvenile Batten disease mice. J. Neuroimmunol. 2011, 230:169-172.
108. De Duve C., et al. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J. 1955, 60:604-617.